Absci Corp. ( (ABSI) ) has released its Q3 earnings. Here is a breakdown of the information Absci Corp. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Absci Corporation is a clinical-stage biopharmaceutical company leveraging generative AI to advance breakthrough therapeutics, focusing on biologics for challenging therapeutic targets.
In its latest earnings report, Absci Corporation highlighted significant progress in its clinical trials, particularly with its ABS-201 program targeting androgenetic alopecia and endometriosis, while also reporting financial results for the third quarter of 2025.
Key financial metrics revealed a decrease in revenue to $0.4 million compared to $1.7 million in the same quarter last year, attributed to a strategic focus on advancing internal programs. Research and development expenses increased to $19.2 million, reflecting the company’s commitment to its pipeline, while net loss widened slightly to $28.7 million. Absci’s cash reserves, however, grew to $152.5 million, ensuring operational funding into the first half of 2028.
Strategically, Absci is reallocating resources to accelerate the development of ABS-201, with Phase 1/2a trials for androgenetic alopecia set to begin in December 2025 and a Phase 2 trial for endometriosis anticipated in late 2026. The company also reported promising interim results for ABS-101 and continued progress in its drug creation partnerships.
Looking ahead, Absci remains focused on advancing its internal pipeline and partnerships, with management expressing confidence in the potential of its AI-driven platform to deliver innovative therapeutics and drive shareholder value.